A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder

Clinical trial NCT00206102 · COMPLETED

Trial details

NCT number: NCT00206102
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

Schizophrenia Schizoaffective Disorder

Start date: 2003-09-01
Primary completion: 2008-10-01
Enrollment: 1098

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.